pfizer news - Search News

Haleon, Pfizer

Pfizer Sells 700 Million Haleon Shares for $3.05 Billion

The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

MarketWatch · 1h

Pfizer Has Sold 700M Haleon Shares

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More.

Business Insider · 16h

Pfizer to sell 700M ordinary shares of Haleon

Pfizer (PFE) announces that it intends to sell approximately 700M ordinary shares in Haleon plc (HLN), representing approximately 7.7% of

Seeking Alpha on MSN · 15h

Pfizer to cut Haleon stake in 700M share sale

Pfizer (NYSE:PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE:HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3%, implying a divestment of approximately 7.

Pfizer, Albert Bourla

STAT · 17h

Defiant, Pfizer CEO talks about Trump, obesity drugs, and the ‘Pfizer machine’

At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's obesity and oncology drugs.

Reuters · 1d

Pfizer going 'all in' on obesity drug development, CEO Bourla says

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive Officer Albert Bourla said at the JPMorgan Healthcare Conference on Monday.

CNBC on MSN · 1d

Pfizer CEO Albert Bourla: Our 2025 focus is on pipeline

Albert Bourla, Pfizer chairman and CEO, joins CNBC's 'Power Lunch' to discuss the company's focus for 2025, whether bird flu is the next pandemic, and more.

11h

Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund

Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider ...

12h

Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

FiercePharma18h

JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

14hon MSN

Pfizer to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner

Pfizer is looking to sell about 700 million ordinary shares in Haleon, its bookrunner J.P. Morgan said on Tuesday, lowering ...

BioSpace18h

Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...

20h

Pfizer’s Growth Potential and Strategic Focus Justify Buy Rating Amid Healthcare Policy Shifts

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer (PFE – Research Report) and keeping the price target at $36.00.Stay ...

Hosted on MSN8h

Pfizer (PFE) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Pfizer (PFE) closed at $26.41, marking a -1.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time, the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Haleon, Pfizer

Pfizer, Albert Bourla

Related topics